



## Treatment Considerations in Cutaneous Melanoma: From Early Stage to Late/Advanced Stage

### References

Amaria RN, Postow M, Burton EM, et al. Neoadjuvant relatlimab and nivolumab in resectable melanoma. *Nature*. 2022;611(7934):155-160. doi:10.1038/s41586-022-05368-8

American Cancer Society. Melanoma Skin Cancer. Accessed September 25, 2023. <https://www.cancer.org/cancer/types/melanoma-skin-cancer.html>

Arance A, de la Cruz-Merino L, Petrella TM, et al. Phase II LEAP-004 study of lenvatinib plus pembrolizumab for melanoma with confirmed progression on a programmed cell death protein-1 or programmed death ligand 1 inhibitor given as monotherapy or in combination. *J Clin Oncol*. 2023;41(1):75-85. doi:10.1200/JCO.22.00221

Ascierto PA, Dréno B, Larkin J, et al. 5-year outcomes with cobimetinib plus vemurafenib in BRAFV600 mutation-positive advanced melanoma: Extended follow-up of the coBRIM study. *Clin Cancer Res*. 2021;27(19):5225-5235. doi:10.1158/1078-0432.CCR-21-0809

Ascierto PA, Lipson EJ, Dummer R, et al. Nivolumab and relatlimab in patients with advanced melanoma that had progressed on anti-programmed death-1/programmed death ligand 1 therapy: Results from the phase I/IIa RELATIVITY-020 trial. *J Clin Oncol*. 2023;41(15):2724-2735. doi:10.1200/JCO.22.02072

Ascierto PA, Stroyakovskiy D, Gogas H, et al. Overall survival with first-line atezolizumab in combination with vemurafenib and cobimetinib in BRAF<sup>V600</sup> mutation-positive advanced melanoma (IMspire150): second interim analysis of a multicentre, randomised, phase 3 study. *Lancet Oncol*. 2023;24(1):33-44. doi:10.1016/S1470-2045(22)00687-8

Atkins MB, Lee SJ, Chmielowski B, et al. Combination dabrafenib and trametinib versus combination nivolumab and ipilimumab for patients with advanced BRAF-mutant melanoma: The DREAMseq trial—ECOG-ACRIN EA6134. *J Clin Oncol*. 2023;41(2):186-197. doi:10.1200/JCO.22.01763

Brahmer JR, Lacchetti C, Schneider BJ, et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology clinical practice guideline. *J Clin Oncol*. 2018;36(17):1714-1768. doi:10.1200/JCO.2017.77.6385

Chesney J, Lewis KD, Kluger H, et al. Efficacy and safety of lifileucel, a one-time autologous tumor-infiltrating lymphocyte (TIL) cell therapy, in patients with advanced melanoma after progression on immune checkpoint inhibitors and targeted therapies: pooled analysis of consecutive cohorts of the C-144-01 study. *J Immunother Cancer*. 2022;10(12):e005755. doi:10.1136/jitc-2022-005755

Daud A, Tsai K. Management of treatment-related adverse events with agents targeting the MAPK pathway in patients with metastatic melanoma. *Oncologist*. 2017;22(7):823-833. doi:10.1634/theoncologist.2016-0456



## Treatment Considerations in Cutaneous Melanoma: From Early Stage to Late/Advanced Stage

Dréno B, Ribas A, Larkin J, et al. Incidence, course, and management of toxicities associated with cobimetinib in combination with vemurafenib in the coBRIM study. *Ann Oncol*. 2017;28(5):1137-1144. doi:10.1093/annonc/mdx040

Dummer R, Ascierto PA, Gogas HJ, et al. Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial. *Lancet Oncol*. 2018;19(5):603-615. doi:10.1016/S1470-2045(18)30142-6

Dummer R, Ascierto PA, Gogas HJ, et al. Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial. *Lancet Oncol*. 2018;19(10):1315-1327. doi:10.1016/S1470-2045(18)30497-2

Dummer R, Hauschild A, Santinami M, et al. Five-year analysis of adjuvant dabrafenib plus trametinib in stage III melanoma. *N Engl J Med*. 2020;383(12):1139-1148. doi:10.1056/NEJMoa2005493

Eggermont AMM, Blank CU, Mandala M, et al. Adjuvant pembrolizumab versus placebo in resected stage III melanoma. *N Engl J Med*. 2018;378(19):1789-1801. doi:10.1056/NEJMoa1802357

Eggermont AMM, Kicinski M, Blank CU, et al. Five-year analysis of adjuvant pembrolizumab or placebo in stage III melanoma. *N Engl J Med Evid*. 2022;1(11). doi:10.1056/EVIDoa2200214

Gutzmer R, Stroyakovskiy D, Gogas H, et al. Atezolizumab, vemurafenib, and cobimetinib as first-line treatment for unresectable advanced BRAF<sup>V600</sup> mutation-positive melanoma (IMspire150): primary analysis of the randomised, double-blind, placebo-controlled, phase 3 trial. *Lancet*. 2020;395(10240):1835-1844. doi:10.1016/S0140-6736(20)30934-X

Hamid O, Lewis KD, Weise AM, et al. Significant durable response with fianlimab (anti-LAG-3) and cemiplimab (anti-PD-1) in advanced melanoma: Post adjuvant PD-1 analysis. *J Clin Oncol*. 2023;41(suppl\_16):9501. doi:10.1200/JCO.2023.41.16\_suppl.9501

Hamid O, Puzanov I, Dummer R, et al. Final analysis of a randomised trial comparing pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory advanced melanoma. *Eur J Cancer*. 2017;86:37-45. doi:10.1016/j.ejca.2017.07.022

Khattak A, Weber JS, Meniawy T, et al. Distant metastasis-free survival results from the randomized, phase 2 mRNA-4157-P201/KEYNOTE-942 trial. *J Clin Oncol*. 2023;41(17\_suppl):LBA9503-LBA9503. doi:10.1200/JCO.2023.41.17\_suppl.LBA9503

Larkin J, Ascierto PA, Dréno B, et al. Combined vemurafenib and cobimetinib in BRAF-mutated melanoma. *N Engl J Med*. 2014;371(20):1867-1876. doi:10.1056/NEJMoa1408868

Larkin J, Chiarion-Sileni V, Gonzalez R, et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. *N Engl J Med*. 2015;373(1):23-34. doi:10.1056/NEJMoa1504030



## Treatment Considerations in Cutaneous Melanoma: From Early Stage to Late/Advanced Stage

Larkin J, Del Vecchio M, Mandalá M, et al. Adjuvant nivolumab versus ipilimumab in resected stage III/IV melanoma: 5-year efficacy and biomarker results from CheckMate 238. *Clin Cancer Res*. 2023;29(17):3352-3361. doi:10.1158/1078-0432.CCR-22-3145

Lee AY, Droppelmann N, Panageas KS, et al. Patterns and timing of initial relapse in pathologic stage II melanoma patients. *Ann Surg Oncol*. 2017;24(4):939-946. doi:10.1245/s10434-016-5642-0

Long GV, Atkinson V, Lo S, et al. Five-year overall survival from the anti-PD1 brain collaboration (ABC Study): randomized phase 2 study of nivolumab (nivo) or nivo+ipilimumab (ipi) in patients (pts) with melanoma brain metastases (mets). *J Clin Oncol*. 2021;39(15\_suppl):9508. doi:10.1200/JCO.2021.39.15\_suppl.9508

Long GV, Flaherty KT, Stroyakovskiy D, et al. Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study. *Ann Oncol*. 2017;28(7):1631-1639. doi:10.1093/annonc/mdx176

Long GV, Hauschild A, Santinami M, et al. Adjuvant dabrafenib plus trametinib in stage III BRAF-mutated melanoma. *N Engl J Med*. 2017;377(19):1813-1823. doi:10.1056/NEJMoa1708539

Long GV, Luke JJ, Khattak MA, et al. Pembrolizumab versus placebo as adjuvant therapy in resected stage IIB or IIC melanoma (KEYNOTE-716): distant metastasis-free survival results of a multicentre, double-blind, randomised, phase 3 trial. *Lancet Oncol*. 2022;23(11):1378-1388. doi:10.1016/S1473-2045(22)00559-9

Long GV, Stroyakovskiy D, Gogas H, et al. Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial. *Lancet*. 2015;386(9992):444-451. doi:10.1016/S0140-6736(15)60898-4

Long GV, Vecchio MD, Weber J, et al. Adjuvant therapy with nivolumab versus placebo in patients with resected stage IIB/C melanoma (CheckMate 76K). *SKIN: The Journal of Cutaneous Medicine*. 2023;7(2),s163. <https://jofskin.org/index.php/skin/article/view/2021/1667>

Luke JJ, Ascierto PA, Khattak MA, et al. Pembrolizumab versus placebo as adjuvant therapy in stage IIB or IIC melanoma: Final analysis of distant metastasis-free survival in the phase 3 KEYNOTE-716 study. *J Clin Oncol*. 2023;41(17\_suppl):LBA9505. doi:10.1200/JCO.2023.41.17\_suppl.LBA9505

National Cancer Institute SEER Program. Cancer Stat Facts: Melanoma of the Skin. Accessed September 25, 2023. <https://seer.cancer.gov/statfacts/html/melan.html>

National Cancer Institute SEER Program. SEER\* Explorer. Melanoma of the Skin. Accessed September 25, 2023. <https://seer.cancer.gov/statistics-network/explorer/application.html>

National Comprehensive Cancer Network. Management of Immunotherapy-Related Toxicities. v.2.2023. Published May 9, 2023. Accessed September 25, 2023. [https://www.nccn.org/professionals/physician\\_gls/pdf/immunotherapy.pdf](https://www.nccn.org/professionals/physician_gls/pdf/immunotherapy.pdf)



## Treatment Considerations in Cutaneous Melanoma: From Early Stage to Late/Advanced Stage

National Comprehensive Cancer Network. Melanoma: Cutaneous. v.2.2023. Published March 10, 2023. Accessed September 25, 2023.

[https://www.nccn.org/professionals/physician\\_gls/pdf/cutaneous\\_melanoma.pdf](https://www.nccn.org/professionals/physician_gls/pdf/cutaneous_melanoma.pdf)

Patel SP, Othus M, Chen Y, et al. Neoadjuvant-adjuvant or adjuvant-only pembrolizumab in advanced melanoma. *N Engl J Med*. 2023;388(9):813-823. doi:10.1056/NEJMoa2211437

Poklepovic AS, Luke JJ. Considering adjuvant therapy for stage II melanoma. *Cancer*. 2020;126(6):1166-1174. doi:10.1002/cncr.32585

Ribas A, Puzanov I, Dummer R, et al. Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial. *Lancet Oncol*. 2015;16(8):908-918. doi:10.1016/S1470-2045(15)00083-2

Robert C, Karaszewska B, Schachter J, et al. Improved overall survival in melanoma with combined dabrafenib and trametinib. *N Engl J Med*. 2015;372(1):30-39. doi:10.1056/NEJMoa1412690

Robert C, Schachter J, Long GV, et al. Pembrolizumab versus ipilimumab in advanced melanoma. *N Engl J Med*. 2015;372(26):2521-2532. doi:10.1056/NEJMoa1503093

Sanchez-Vega F, Mina M, Armenia J, et al. Oncogenic signaling pathways in the cancer genome atlas. *Cell*. 2018;173(2):321-337.e10. doi:10.1016/j.cell.2018.03.035

Schachter J, Ribas A, Long GV, et al. Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006). *Lancet*. 2017;390(10105):1853-1862. doi:10.1016/S0140-6736(17)31601-X

Schreck KC, Patel MP, Wemmer J, Grossman SA, Peters KB. RAF and MEK inhibitor therapy in adult patients with brain tumors: a case-based overview and practical management of adverse events. *Neurooncol Pract*. 2020;7(4):369-375. doi:10.1093/nop/npaa006

Tanda ET, Vanni I, Boutros A, et al. Current state of target treatment in BRAF mutated melanoma. *Front Mol Biosci*. 2020;7:154. doi:10.3389/fmolb.2020.00154

Tawbi HA, Hodi S, Lipson EJ, et al. Nivolumab (NIVO) plus relatlimab (RELA) vs NIVO in previously untreated metastatic or unresectable melanoma: 2-year results from RELATIVITY-047. *J Clin Oncol*. 2023;41(16\_suppl):Abstr9502. doi:10.1200/JCO.2023.41.16\_suppl.9502

Tawbi HA, Schadendorf D, Lipson EJ, et al. Relatlimab and nivolumab versus nivolumab in untreated advanced melanoma. *N Engl J Med*. 2022;386(1):24-34. doi:10.1056/NEJMoa2109970

Taylor J, Gandhi A, Gray E, Zaenker P. Checkpoint inhibitor immune-related adverse events: A focused review on autoantibodies and B cells as biomarkers, advancements and future possibilities. *Front Immunol*. 2023;13:991433. doi:10.3389/fimmu.2022.991433

Trinh S, Le A, Gowani S, La-Beck NM. Management of immune-related adverse events associated with immune checkpoint inhibitor therapy: A minireview of current clinical guidelines. *Asia Pac J Oncol Nurs*. 2019;6(2):154-160. doi:10.4103/apjon.apjon\_3\_19



## Treatment Considerations in Cutaneous Melanoma: From Early Stage to Late/Advanced Stage

Vanderwalde AM, Moon J, Kendra K, et al. Ipilimumab plus nivolumab versus ipilimumab alone in patients with metastatic or unresectable melanoma that did not respond to anti-PD-1 therapy. 2022 American Association for Cancer Research Annual Meeting. Abstr CT013.

<https://www.abstractsonline.com/pp8/#!/10517/presentation/20155>

Versluis JM, Menzies AM, Sikorska K, et al. Survival update of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma in the OpACIN and OpACIN-neo trials. *Ann Oncol.* 2023;34(4):420-430. doi:10.1016/j.annonc.2023.01.004

Weber J, Mandala M, Del Vecchio M, et al. Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma. *N Engl J Med.* 2017;377(19):1824-1835. doi:10.1056/NEJMoa1709030

Wei Y, Li Z. LAG3-PD-1 combo overcome the disadvantage of drug resistance. *Front Oncol.* 2022;12:831407. doi:10.3389/fonc.2022.831407

Wolchok JD, Chiarion-Sileni V, Gonzalez R, et al. Long-term outcomes with nivolumab plus ipilimumab or nivolumab alone versus ipilimumab in patients with advanced melanoma. *J Clin Oncol.* 2022;40(2):127-137. doi:10.1200/JCO.21.02229

Wolchok JD, Chiarion-Sileni V, Gonzalez R, et al. Overall survival with combined nivolumab and ipilimumab in advanced melanoma. *N Engl J Med.* 2017;377(14):1345-1356. doi:10.1056/NEJMoa1709684